Simple Plex Immunoassays for Neurological Disease Research

Simple Plex Assays Detect Neurological Biomarkers with Precision

Recent advances in biomarker discovery have identified key indicators in blood and cerebrospinal fluid (CSF), such as phospho-tau 217, GFAP, and amyloid beta 1-40/42, that show great promise across a variety of neurological disorders, including Alzheimer’s disease, Parkinsons, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and traumatic brain injury (TBI).

The ability to detect these biomarkers at ultra-low levels, particularly those traditionally measurable only in CSF, has the potential to revolutionize how brain injuries and diseases are understood. Simple Plex Assays enable the detection of critical neurological biomarkers—such as Neurofilament Light (NF-L), Tau, GFAP, and others associated with brain injury and disease—in CSF, serum, or plasma. By facilitating early detection without relying on invasive methods, Simple Plex Assays can help advance the understanding of disease pathology and the long-term effects of neurological disorders.

Simple Plex assays offer highly sensitive assays for CSF and blood applications, at sub-picogram levels, with full sample detectability.

Why Use Simple Plex Technology for Neurological Biomarker Detection?

With exceptional precision, efficiency, and minimized cross-reactivity, Simple Plex Assays can help in your neuroscience research by enabling the rapid, large-scale collection of biomarker data—making new insights and discoveries possible.

Simple Plex Assays Span Neurological Disease, Neuroinflammation & Injury

Evaluate key neurological targets with Simple Plex Assays now including the new Simple Plex Ultra-Sensitive Assays for enhanced detection. Ultra-Sensitive Assays offer femtogram-level sensitivity, enabling earlier insights into disease processes and pathology.

Key analytes available in Simple Plex Assays for the study of neurological health and disease including neuroinflammation, neurodegeneration, synaptic dysfunction, neuronal injury/ traumatic brain injury, and neurotrophic factors. 

Neurodegeneration and Biomarker Detection with Simple Plex Assays

Neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (AL), and other related disorders, are marked by the progressive loss of neuronal structure and function, leading to cognitive decline, motor impairments, and other debilitating symptoms. Early detection and monitoring are key to understanding disease progression and developing effective treatments. Biomarkers found in blood and cerebrospinal fluid (CSF) are transforming how neurodegenerative conditions are diagnosed, enabling precision medicine and advancing research in this critical area. Simple Plex Assays offer highly sensitive and reliable detection of key biomarkers associated with neurodegeneration, including NF-L, NF-H.

NF-L: A Game-changing Biomarker for Neurological Disorders

The utility of NF-L as a neurodegeneration biomarker is enhanced by its ability to be measured in less invasive blood samples rather than CSF. However, because NF-L exists in very low concentrations in blood (in the low picogram per milliliter range), a highly sensitive assay is required to deliver accurate, reproducible data. In response, researchers have turned to advanced immunoassay platforms that combine sensitivity with efficiency. These systems incorporate enhanced detection methods, enabling the detection of low abundance biomarkers that traditional assays like ELISA might miss. 

Assessing Neuroinflammation

Assessing neuroinflammation with immunoassays involves quantifying biomarkers associated with glial activation, immune response, and cytokine signaling, which help elucidate underlying neuroinflammatory processes. Glial fibrillary acidic protein (GFAP) is a specific astrocytic marker indicating astrocyte activation and injury. Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) serves as a key microglial biomarker, reflecting microglial activity, particularly in neurodegenerative conditions like Alzheimer’s disease. Chemokine and cytokine assays enable the evaluation of pro-inflammatory (e.g., IL-1β, TNF-α) and anti-inflammatory (e.g., IL-4, IL-10) signaling molecules, offering insights into the balance of neuroimmune responses. Together, these biomarkers provide a comprehensive profile of neuroinflammatory states, facilitating research and potential clinical applications.

Alzheimer’s Disease and Protein Misfolding Pathologies 

Biomarkers in blood and cerebrospinal fluid (CSF) have emerged as valuable tools for diagnosing and monitoring protein misfolding pathologies and disease progression. Amyloid-beta, phospho-tau 217 (pTau 217), and alpha-synuclein biomarkers offer invaluable insights into protein misfolding pathologies:

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor impairments resulting from the loss of dopaminergic neurons in the brain. Early and accurate detection of Parkinson's disease is critical for improving disease management and advancing research into effective treatments. Simple Plex Assays enable the highly sensitive detection of key Parkinson’s-related biomarkers, including Dopa Decarboxylase (DDC), alpha-synuclein, and PARK-7. These biomarkers play essential roles in understanding the pathology of Parkinson’s disease:

• Dopa Decarboxylase (DDC): This enzyme is central to dopamine synthesis, and its dysregulation can provide insight into the neuronal processes impaired in Parkinson’s disease.
• Alpha-synuclein: A hallmark of Parkinson’s pathology, alpha-synuclein aggregation in the brain is a key contributor to neuronal dysfunction and degeneration. Changes in alpha-synuclein levels in CSF or blood are promising indicators for early detection and tracking disease progression.
• PARK7- also known as DJ-1, is a cytoplasmic protein that belongs to the ThiJ/Pfp1/DJ-1 superfamily of highly conserved proteins that function as protein chaperones, catalases, proteases and kinases. Park7 is widely expressed in the brain as well as in peripheral tissues. Park7 is a redox-sensitive protein that has been ascribed various functions including that as a redox sensor and antioxidant protein. Mutations in Park7 are associated with a small percentage of hereditary early onset Parkinson's disease.

Neuronal Injury and TBI Research 

Traumatic Brain Injury (TBI) is a significant global health challenge, accounting for countless lives lost and causing long-term disabilities. Beyond the immediate trauma, emerging evidence highlights the pivotal role of systemic inflammation—not merely as a consequence of TBI, but potentially as a driver of ongoing neurological damage. This inflammatory cascade may hold the key to improving outcomes for TBI patients, making its understanding and mitigation a critical focus of research.

Recognizing the complexity of TBI-associated neuroinflammation, Simple Plex assays provide powerful tools for advancing TBI research. These assays offer highly sensitive and reliable quantification of key brain injury biomarkers, including GFAP, UCH-L1, NF-L, S100B, Total Tau, and Enolase 2. Designed to detect these biomarkers with precision across a wide dynamic range—even at extremely low concentrations—Simple Plex assays allow researchers to capture the subtle yet critical changes underpinning TBI progression and recovery.

Simple Plex Neuroscience Assays

Resources